Cure SMA - North Texas Chapter

More treatment progress!

Scholar Rock has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for apitegromab, an investigational therapy for spinal muscular atrophy.

Scholar Rock anticipates FDA acceptance of the BLA within 30 days of resubmission and a review period of up to six months from the date of resubmission.

Cure SMA will continue to monitor progress and share updates with the community.

Click the link to read the full update: https://www.curesma.org/scholar-rock-resubmits-biologics-license-application-bla-for-apitegromab-to-the-fda/

Incredible news for the SMA community!

Incredible news for the SMA community! Novartis has received FDA approval for Itvisma® (onasemnogene abeparvovec-brve)—a new SMA treatment option bringing greater independence and new possibilities for individuals living with SMA.

This is a meaningful step forward in our collective mission to address the critical unmet needs of older individuals living with SMA while empowering families with more options for care.

Learn more about this exciting development and what it means for individuals and families impacted by SMA: https://www.curesma.org/novartis-receives-fda-approval-of-itvisma-for-the-treatment-of-sma/

Please sign and share widely with your friends, family, etc!

Cure SMA is advocating for additional federal funding for Spinal Muscular Atrophy research and we need your help! It only takes a minute or two to fill out the form below. You will first click your state, check that you are from that state at the bottom, and add in your information. We would greatly appreciate if you could share widely with your networks🧡💜

You can sign on here:https://www.curesma.org/wp-content/uploads/2025/01/Cure-SMA-SMA-Research-Signon-Letter-State-Links.pdf